← Back to Search

CXC Chemokine Receptor Antagonist

Advanced NSCLC Patients for Non-small Cell Lung Cancer

Q: Do I qualify to partake in this scientific experiment?

<p>Eligible patients for this clinical trial should have non-<a href="https://www.withpower.com/clinical-trials/small-cell-lung-cancer">small cell lung cancer</a> and be of legal age. A maximum of 28 people may take part in the study.</p>

Phase 2

Waitlist Available

Led By Salman Punekar, Punekar

Research Sponsored by NYU Langone Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to end of survival follow-up (up to month 36)

Awards & highlights

Study Summary

This trial tests an oral drug to treat advanced lung cancer with a mutant gene.

Eligible Conditions

Non-small Cell Lung Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to end of survival follow-up (up to month 36)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to end of survival follow-up (up to month 36)

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to end of survival follow-up (up to month 36) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Progression Free Survival (PFS)

Secondary outcome measures

Overall Survival (OS)

Percent of Participants who Experience Complete Response (CR)

Percent of Participants who Experience Grade 1 Treatment-Related Adverse Events per CTCAE 5.0

+7 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Advanced NSCLC PatientsExperimental Treatment2 Interventions

Patients with KRASG12C mutant NSCLC will receive ladarixin and sotorasib in combination.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Sotorasib

2021

Completed Phase 1

~370

Ladarixin

2016

Completed Phase 2

~120

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor

1,367 Previous Clinical Trials

839,761 Total Patients Enrolled

Salman Punekar, PunekarPrincipal InvestigatorNYU Langone Health

Salman Punekar, MDPrincipal InvestigatorNYU Langone Health

1 Previous Clinical Trials

40 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this trial have an upper age restriction?

"This research is recruiting individuals aged 18 and up to 100 years old."

Answered by AI

What perils are associated with advanced non-small cell lung cancer?

"Advanced NSCLC Patients garnered a safety rating of 2, given the Phase 2 trial status and the available data suggesting general security but no clinical assurance of efficacy."

Answered by AI

Do I qualify to partake in this scientific experiment?

"Eligible patients for this clinical trial should have non-small cell lung cancer and be of legal age. A maximum of 28 people may take part in the study."

Answered by AI

Are there currently any openings to participate in this experiment?

"The clinicaltrial.gov data shows that this particular trial is not presently recruiting patients, as the last update was posted on April 4th 2023. Nevertheless, there are 1,929 other studies actively searching for volunteers at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

2024. "Ladarixin With Sotorasib in Advanced NSCLC - Phase II". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05815186.